13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001727492
Total reported value
$2.1B
$2.1B
14 檔
13.5%
According to the latest 13F quarterly dataset, Caligan Partners LP managed an equity portfolio of $2.1B at the end of Q4 2024, spanning 14 distinct U.S. exchange-listed positions.
In Q4 2024, Caligan Partners LP displayed an active expansion posture, initiating 4 new positions and adding to 5 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LQDA | Liquidia CORP | Stock-Other | 29.26% | +10.06% | — | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 16.90% | — | — | |
| 3 | EXEL | Exelixis Inc | Stock-Healthcare | 12.87% | -0.45% | — | |
| 4 | EOLS | Evolus Inc | Stock-Other | 7.53% | — | +22.74% | |
| 5 | ANIK | Anika Therapeutics Inc | Stock-Other | 5.98% | -0.39% | — | |
| 6 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 5.71% | — | +15.96% | |
| 7 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 5.21% | -0.04% | +8.03% | |
| 8 | SG7 | Sage Therapeutics Inc | Stock-Other | 4.20% | — | — | |
| 9 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 3.51% | — | +47.92% | |
| 10 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 3.15% | -5.00% | EXIT | |
| 11 | ✓ | Merus N V | Stock-Other | 2.72% | — | — | |
| 12 | ABVX | Abivax Sa-adr | Stock-Other | 1.39% | -1.06% | — | |
| 13 | ✓ | Verrica Pharmaceuticals Inc | Stock-Other | 1.32% | — | — | |
| 14 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.27% | — | -42.68% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SG7 | Sage Therapeutics Inc | +4.2% | NEW | New buy |
| 2 | VRNA | Verona Pharma PLC - Adr | +3.8% | — | Unchanged |
| 3 | LQDA | Liquidia CORP | +3.5% | — | Unchanged |
| 4 | ✓ | Merus N V | +2.7% | NEW | New buy |
| 5 | ABVX | Abivax Sa-adr | +1.4% | NEW | New buy |
| 6 | ✓ | Verrica Pharmaceuticals Inc | +1.3% | NEW | New buy |
| 7 | EXEL | Exelixis Inc | +0.3% | — | Unchanged |
| 8 | BCRX | Biocryst Pharmaceuticals Inc | -0.5% | +15.96% | Add |
| 9 | OTLK | Outlook Therapeutics Inc | -0.5% | EXIT | Sold out |
| 10 | MLYS | Mineralys Therapeutics Inc | -0.6% | +3.06% | Add |
| 11 | ENTA | Enanta Pharmaceuticals Inc | -0.8% | -42.68% | Trim |
| 12 | NBP | Novabridge Biosciences | -1.4% | EXIT | Sold out |
| 13 | YMABUSD | Y-mabs Therapeutics Inc | -1.5% | +47.92% | Add |
| 14 | AGIO | Agios Pharmaceuticals Inc | -3% | +8.03% | Add |
| 15 | EOLS | Evolus Inc | -3.7% | +22.74% | Add |
| 16 | ANIK | Anika Therapeutics Inc | -5.3% | — | Unchanged |
According to official SEC Form 13F filings, Caligan Partners LP reported a total U.S. public equity portfolio value of $2.1B across 14 disclosed positions in Q4 2024.
During Q4 2024, Caligan Partners LP's top holdings by market value included LQDA (29.3%)、VRNA (16.9%)、EXEL (12.9%). The largest single position, LQDA, represented 29.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LQDA, VRNA, EXEL) accounted for 13.5% of total reported equity market value during Q4 2024.
Top New Position Initiated
SG7
市值: $16.6M
Top Position Liquidated / Trimmed
NBP
前期市值: $4.3M
In Q4 2024, Caligan Partners LP made 12 total portfolio adjustments, initiating 4 new buys, adding to 5 positions, trimming 1 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.